• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Synergistic miRNA Combinations Mitigate Doxorubicin-Induced Cardiotoxicity: Are We Ready for Clinical Translation?

作者信息

Sepúlveda Pilar

机构信息

Regenerative Medicine and Heart Transplantation Unit, Health Research Institute Hospital la Fe, Valencia, Spain; Hospital Universitari i Politècnic La Fe, Valencia, Spain; Department of Pathology, University of Valencia, Valencia, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares, Carlos III Institute of Health, Madrid, Spain.

出版信息

JACC CardioOncol. 2025 Jun;7(4):411-413. doi: 10.1016/j.jaccao.2025.04.002.

DOI:10.1016/j.jaccao.2025.04.002
PMID:40537189
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12228129/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b08/12228129/63742d3a5077/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b08/12228129/63742d3a5077/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b08/12228129/63742d3a5077/ga1.jpg

相似文献

1
Synergistic miRNA Combinations Mitigate Doxorubicin-Induced Cardiotoxicity: Are We Ready for Clinical Translation?协同作用的微小RNA组合减轻阿霉素诱导的心脏毒性：我们准备好进行临床转化了吗？
JACC CardioOncol. 2025 Jun;7(4):411-413. doi: 10.1016/j.jaccao.2025.04.002.
2
Mitigation of Doxorubicin Cardiotoxicity With Synergistic miRNA Combinations Identified Using Combinatorial Genetics en masse (CombiGEM).使用大规模组合遗传学（CombiGEM）鉴定的协同miRNA组合减轻阿霉素心脏毒性
JACC CardioOncol. 2025 Jun;7(4):396-410. doi: 10.1016/j.jaccao.2025.03.007. Epub 2025 May 13.
3
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.用于降低癌症患者心脏毒性的不同蒽环类衍生物。
Cochrane Database Syst Rev. 2006 Oct 18(4):CD005006. doi: 10.1002/14651858.CD005006.pub2.
4
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.用于降低癌症患者心脏毒性的不同蒽环类衍生物。
Cochrane Database Syst Rev. 2010 Mar 17(3):CD005006. doi: 10.1002/14651858.CD005006.pub3.
5
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.用于降低癌症患者心脏毒性的不同蒽环类衍生物。
Cochrane Database Syst Rev. 2010 May 12;2010(5):CD005006. doi: 10.1002/14651858.CD005006.pub4.
6
Traditional Chinese medicine protects against doxorubicin cardiotoxicity via epigenetic modification and beyond.传统中药通过表观遗传修饰及其他方式预防阿霉素心脏毒性。
Phytomedicine. 2025 Sep;145:157020. doi: 10.1016/j.phymed.2025.157020. Epub 2025 Jun 25.
7
Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.儿童癌症治疗期间及治疗后用于治疗蒽环类药物引起的有症状和无症状心脏毒性的医学干预措施。
Cochrane Database Syst Rev. 2016 Aug 23;2016(8):CD008011. doi: 10.1002/14651858.CD008011.pub3.
8
Nucleolin protects against doxorubicin-induced cardiotoxicity via upregulating microRNA-21.核仁素通过上调 microRNA-21 来对抗阿霉素诱导的心脏毒性。
J Cell Physiol. 2018 Dec;233(12):9516-9525. doi: 10.1002/jcp.26854. Epub 2018 Jul 3.
9
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.右雷佐生预防或减少接受蒽环类抗生素治疗的癌症成人和儿童的心脏毒性。
Cochrane Database Syst Rev. 2022 Sep 27;9(9):CD014638. doi: 10.1002/14651858.CD014638.pub2.
10
Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.儿童癌症治疗期间及治疗后用于治疗蒽环类药物引起的有症状和无症状心脏毒性的医学干预措施。
Cochrane Database Syst Rev. 2011 Sep 7(9):CD008011. doi: 10.1002/14651858.CD008011.pub2.

本文引用的文献

1
Mitigation of Doxorubicin Cardiotoxicity With Synergistic miRNA Combinations Identified Using Combinatorial Genetics en masse (CombiGEM).使用大规模组合遗传学（CombiGEM）鉴定的协同miRNA组合减轻阿霉素心脏毒性
JACC CardioOncol. 2025 Jun;7(4):396-410. doi: 10.1016/j.jaccao.2025.03.007. Epub 2025 May 13.
2
Modeling Cardiotoxicity in Pediatric Oncology Patients Using Patient-Specific iPSC-Derived Cardiomyocytes Reveals Downregulation of Cardioprotective microRNAs.使用患者特异性诱导多能干细胞衍生的心肌细胞对儿科肿瘤患者的心脏毒性进行建模，揭示了心脏保护微小RNA的下调。
Antioxidants (Basel). 2023 Jul 3;12(7):1378. doi: 10.3390/antiox12071378.
3
MicroRNA-4732-3p Is Dysregulated in Breast Cancer Patients with Cardiotoxicity, and Its Therapeutic Delivery Protects the Heart from Doxorubicin-Induced Oxidative Stress in Rats.
微小RNA-4732-3p在患有心脏毒性的乳腺癌患者中表达失调，其治疗性递送可保护大鼠心脏免受阿霉素诱导的氧化应激损伤。
Antioxidants (Basel). 2022 Sep 30;11(10):1955. doi: 10.3390/antiox11101955.
4
Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study.针对心力衰竭患者的新型靶向微小RNA-132反义疗法：首例人体1b期随机、双盲、安慰剂对照研究结果
Eur Heart J. 2021 Jan 7;42(2):178-188. doi: 10.1093/eurheartj/ehaa898.
5
A Three-Way Combinatorial CRISPR Screen for Analyzing Interactions among Druggable Targets.一种用于分析可成药靶点之间相互作用的三向组合CRISPR筛选
Cell Rep. 2020 Aug 11;32(6):108020. doi: 10.1016/j.celrep.2020.108020.
6
Atorvastatin enhances the therapeutic efficacy of mesenchymal stem cells-derived exosomes in acute myocardial infarction via up-regulating long non-coding RNA H19.阿托伐他汀通过上调长链非编码 RNA H19 增强间充质干细胞来源的外泌体在急性心肌梗死中的治疗效果。
Cardiovasc Res. 2020 Feb 1;116(2):353-367. doi: 10.1093/cvr/cvz139.
7
Molecular mechanism of doxorubicin-induced cardiomyopathy - An update.多柔比星诱导性心肌病的分子机制——最新研究进展。
Eur J Pharmacol. 2018 Jan 5;818:241-253. doi: 10.1016/j.ejphar.2017.10.043. Epub 2017 Oct 23.
8
Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.蒽环类药物心脏毒性的氧化应激、氧化还原信号和金属螯合作用及药理学心脏保护作用。
Antioxid Redox Signal. 2013 Mar 10;18(8):899-929. doi: 10.1089/ars.2012.4795. Epub 2012 Oct 12.